BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gómez-Seguí I, Fernández-Zarzoso M, de la Rubia J. A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura. Expert Rev Hematol 2020;13:1153-64. [PMID: 32876503 DOI: 10.1080/17474086.2020.1819230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee HT, Park UB, Jeong TJ, Gu N, Lee SH, Kim Y, Heo YS. High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP. Biochem Biophys Res Commun 2021;567:49-55. [PMID: 34144500 DOI: 10.1016/j.bbrc.2021.06.030] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Hanna RM, Henriksen K, Kalantar-Zadeh K, Ferrey A, Burwick R, Jhaveri KD. Thrombotic Microangiopathy Syndromes-Common Ground and Distinct Frontiers. Adv Chronic Kidney Dis 2022;29:149-160.e1. [PMID: 35817522 DOI: 10.1053/j.ackd.2021.11.006] [Reference Citation Analysis]
3 Gómez-Seguí I, Pascual Izquierdo C, de la Rubia Comos J. Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura. Expert Rev Hematol 2021;14:707-19. [PMID: 34275393 DOI: 10.1080/17474086.2021.1956898] [Reference Citation Analysis]
4 Shin C, Kim SS, Jo YH. Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications. Mol Ther Oncolytics 2021;22:166-79. [PMID: 34514097 DOI: 10.1016/j.omto.2021.08.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]